Advertisement

Journal of Neural Transmission

, Volume 126, Issue 1, pp 19–25 | Cite as

Genetic variations in the ADCK1 gene predict paliperidone palmitate efficacy in Han Chinese patients with schizophrenia

  • Yun-Ai Su
  • Chad Bousman
  • Qian Li
  • Ji-Tao Li
  • Jing-Yu Lin
  • Tian-Mei SiEmail author
Psychiatry and Preclinical Psychiatric Studies - Original Article

Abstract

Genome-wide association study results have linked ADCK1 genetic variation with paliperidone efficacy in a European cohort. However, the generalizability of this locus to non-European populations is unknown. Han Chinese schizophrenia patients (n = 159) were treated with paliperidone palmitate and symptom severity was assessed over 3 months. Examination of 13 ADCK1 genetic variants revealed two single nucleotide polymorphisms (rs12590199, rs11159291) and one haplotype (rs2364747–rs12590199) associated with paliperidone palmitate response. Future work into ADCK1’s function and its potential interaction with paliperidone is warranted.

Keywords

Schizophrenia Paliperidone palmitate ADCK1 Pharmacogenetics 

Notes

Acknowledgements

This research was supported by the National Natural Science Foundation of China (Nos. 81630031, 81571312), Capital Medical Development Research Fund (2016-1-4111), Beijing Municipal Science and Technology Project (Z171100000117016) and National Key Technology R&D Program (2015BAI13B01).

Supplementary material

702_2018_1953_MOESM1_ESM.docx (941 kb)
Supplementary material 1 (DOCX 942 KB)

References

  1. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, Karczewski KJ, Park J, Hitz BC, Weng S, Cherry JM, Snyder M (2012) Annotation of functional variation in personal genomes using RegulomeDB. Genome Res 22(9):1790–1797.  https://doi.org/10.1101/gr.137323.112 Google Scholar
  2. Brandl EJ, Kennedy JL, Muller DJ (2014) Pharmacogenetics of antipsychotics. Can J Psychiatry 59(2):76–88.  https://doi.org/10.1177/070674371405900203 Google Scholar
  3. Consortium GT (2013) The Genotype-tissue expression (GTEx) project. Nat Genet 45(6):580–585.  https://doi.org/10.1038/ng.2653 Google Scholar
  4. Hough D, Lindenmayer JP, Gopal S, Melkote R, Lim P, Herben V, Yuen E, Eerdekens M (2009) Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 33(6):1022–1031.  https://doi.org/10.1016/j.pnpbp.2009.05.014 Google Scholar
  5. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M (2007) Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 90(1–3):147–161.  https://doi.org/10.1016/j.schres.2006.09.012 Google Scholar
  6. Li Q, Wineinger NE, Fu DJ, Libiger O, Alphs L, Savitz A, Gopal S, Cohen N, Schork NJ (2017) Genome-wide association study of paliperidone efficacy. Pharmacogenet Genom 27(1):7–18.  https://doi.org/10.1097/FPC.0000000000000250 Google Scholar
  7. Marder SR, Davis JM, Chouinard G (1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58(12):538–546Google Scholar
  8. Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, Lowy A (2007) Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 62(12):1363–1370.  https://doi.org/10.1016/j.biopsych.2007.01.017 pii].Google Scholar
  9. Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, Eerdekens M (2008) Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 69(5):817–829Google Scholar
  10. Mi W, Liu F, Liu Y, Du B, Xiao W, Li L, Huang L, Lu T, He J, Shi L, Yue W, Zhang H (2016) Association of ABCB1 gene polymorphisms with efficacy and adverse reaction to risperidone or paliperidone in han chinese schizophrenic patients. Neurosci Bull 32 (6):547–549.  https://doi.org/10.1007/s12264-016-0050-9 Google Scholar
  11. Narum SR (2006) Beyond bonferroni: less conservative analyses for conservation genetics. Conserv Genet 7(5):783–787Google Scholar
  12. Pouget JG, Shams TA, Tiwari AK, Muller DJ (2014) Pharmacogenetics and outcome with antipsychotic drugs. Dialogues Clin Neurosci 16(4):555–566Google Scholar
  13. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81(3):559–575.  https://doi.org/10.1086/519795 Google Scholar
  14. Wang D, Fu DJ, Wu X, Shapiro A, Favis R, Savitz A, Chung H, Alphs L, Gopal S, Haas M, Cohen N, Li Q (2015) Large-scale candidate gene study to identify genetic risk factors predictive of paliperidone treatment response in patients with schizophrenia. Pharmacogenet Genom 25(4):173–185.  https://doi.org/10.1097/FPC.0000000000000122 Google Scholar
  15. Zhang JP, Malhotra AK (2011) Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol 7(1):9–37.  https://doi.org/10.1517/17425255.2011.532787 Google Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2018

Authors and Affiliations

  • Yun-Ai Su
    • 1
  • Chad Bousman
    • 2
  • Qian Li
    • 1
  • Ji-Tao Li
    • 1
  • Jing-Yu Lin
    • 1
  • Tian-Mei Si
    • 1
    Email author
  1. 1.Peking University Sixth Hospital and Peking University Institute of Mental Health and Key Laboratory of Mental Health, Ministry of Health (Peking University) and National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital)BeijingChina
  2. 2.Departments of Medical Genetics, Psychiatry, and Physiology and PharmacologyUniversity of CalgaryCalgaryCanada

Personalised recommendations